Published on 13 March 2013
Health authority perspective on biosimilars
Author(s): Brian Godman, BSc, PhD
DOI: 10.5639/gabij.2013.0201.010
9.962 views
Published on 13 March 2013
Author(s): Brian Godman, BSc, PhD
DOI: 10.5639/gabij.2013.0201.010
9.962 views
Published on 06 March 2013
Author(s): Sabine Vogler, PhD, Nina Zimmermann, MA
generics, generics uptake, medicines, monitoring, prescribing, rational use of medicines, sickness funds
DOI: 10.5639/gabij.2013.0202.027
42.451 views
Published on 06 March 2013
Author(s): Marc Maliepaard, PhD, Yang Yu, PharmD, Professor Hubert GM Leufkens, PharmD, PhD
bioequivalence, drug safety, generics, immunosuppression, regulation
DOI: 10.5639/gabij.2013.0202.019
24.599 views
Published on 12 February 2013
Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath
biosimilar, comparability, quality, risk, safety
DOI: 10.5639/gabij.2013.0201.007
13.762 views
Published on 07 February 2013
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2013.0201.006
13.274 views
Published on 11 January 2013
Author(s): Chang Chiann, PhD, Leonardo de Souza Teixeira, PhD, Fabiana Fernandes de Santana e Silva Cardoso, MSc, Isabela da Costa César, PhD, Gerson Antônio Pianetti, PhD
biosimilarity, complex drugs, Latin America
DOI: 10.5639/gabij.2013.0202.021
20.798 views
Published on 11 January 2013
Author(s): Fereshteh Barei, PhD, Professor Claude Le Pen, PhD, Steven Simoens, MSc, PhD
competition strategy, product portfolio, re-innovation, super generics, technology platforms
DOI: 10.5639/gabij.2013.0201.011
198.409 views
Published on 11 December 2012
Author(s): Christoph Baumgärtel, MD, MSc
DOI: 10.5639/gabij.2013.0201.003
12.996 views
Published on 29 November 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2013.0201.002
14.177 views
Published on 22 November 2012
Author(s): Professor Abdol Majid Cheraghali, PharmaD, PhD
biopharmaceuticals, biosimilars, Iran, pharmacovigilance
DOI: 10.5639/gabij.2013.0201.008
26.123 views
Published on 22 November 2012
Author(s): Michael S Reilly, Esq, Richard O Dolinar, MD
biologicals, biosimilars, FDA guidelines, patient safety, pharmacovigilance
DOI: 10.5639/gabij.2013.0201.014
23.077 views
Published on 14 November 2012
Author(s): Professor Philip D Walson, MD
DOI: 10.5639/gabij.2012.0103-4.037
10.613 views